Form 4 for ORIC Oric Pharmaceuticals, Inc.
Accepted 2023-06-28 00:00:00 ET · period of report 2023-06-26 · accession 0001209191-23-040090 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-28 | 2023-06-26 | ORIC | Chacko Jacob | Pres, CEO, Dir | S - Sale | $8.03 | -20.0K | 800.7K | -2% | -$160.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-26 | S | D | 20,000 | $8.03 | 800,652 | D | — | — | (F2) Represents the weighted average share price of an aggregate total of 20,000 shares sold in the price range of $8.00 to $8.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. (F3) Includes 4,000 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. |